Although it was probably not in serious jeopardy, Bristol-Myers Squibb’s shareholders voted today to approve the acquisition of Celgene Corporation for about $74 billion.
Source: www.biospace.com
Bristol-Myers Squibb Co. announced that its shareholders have approved the Company’s $74 billion acquisition of Celgene Corp. More than 75% of shareholders voted in favor of the Celgene merger agreement, while 24% of shareholders voted against the deal, with less than 1% abstained. The deal is expected to be closed in the third quarter this year, and was first announced in January 2019.
